Homology Class Action: Levi & Korsinsky Reminds Homology Medicines, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 24, 2022 - FIXX
New York, New York--(Newsfile Corp. - May 24, 2022) - Levi & Korsinsky, LLP notifies investors in Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) of a class action securities lawsuit.
The lawsuit on behalf of Homology investors has been commenced in the the United States District Court for the Central District of California. Affected investors purchased or otherwise acquired certain Homology Medicines, Inc. securities between June 10, 2019 and February 18, 2022. Follow the link below to get more information and be contacted by a member of our team:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500. There is no cost or obligation to you.
Cannot view this video? Visit:
Homology Medicines, Inc. NEWS - FIXX NEWS
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) the Company had overstated the efficacy and risk mitigation of its lead product candidate, HMI-102; (ii) accordingly, it was unlikely that the Company would be able to commercialize HMI102 in its present form; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
WHAT THIS MEANS TO SHAREHOLDERS: If you suffered a loss in Homology during the relevant timeframe, you have until May 24, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. Discuss your rights with our legal team without cost or obligation.
PROTECT YOUR FINANCIAL INTERESTS: Complete this brief submission form https://www.zlk.com/pslra-1/homology-medicines-inc-loss-submission-form?prid=27660&wire=5 or call 212-363-7500 to discuss the case.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/125136